Acalabrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
binimetinib
MEK1/2 kinase inhibitor · Antineoplastic agent
MEK1/2 kinase inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12 →
- AcalabrutinibSevereDatabaseDDInter
- AvapritinibSevereDatabaseDDInter
- CabozantinibSevereDatabaseDDInter
- DasatinibSevereDatabaseDDInter
Mechanism
Binimetinib is an orally bioavailable MEK1/2 kinase inhibitor.
Indications
unresectable or metastatic melanoma with a BRAF V600E or V600K mutation (in combination with encorafenib)combination with BRAF inhibitors for melanomas that harbor a mutation at position 600 in BRAF
Dosing
- Renal adjustment
- Impaired renal function does not impact drug elimination.
- Hepatic adjustment
- After moderate to severe hepatic impairment, the area under the curve (AUC) is increased 2-fold.
Pharmacokinetics
Half-life
3.5 h (elimination)
Side effects
Common
headachepyrexiaarthralgias
Serious
- cardiac toxicities
- ocular toxicities
Pregnancy & lactation
Pregnancy
D
Drug interactions
Avapritinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cabozantinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Dasatinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Deferasirox
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drotrecogin Alfa
Severe
Database
Clinical effect not specified
Source: DDInter
Ibritumomab
Severe
Database
Clinical effect not specified
Source: DDInter
Ibrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Inotersen
Severe
Database
Clinical effect not specified
Source: DDInter
Leflunomide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Lomitapide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Mipomersen
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Related guidelines
Heart failure in diabetes
RSSDI · Cardiology · 2023
Beta-blockers in hypertension
MOHFW · Cardiology · 2024
GI bleeding on antiplatelet or anticoagulant therapy
CSI · Cardiology · 2020
ST-elevation myocardial infarction
CSI · Cardiology · 2020
Acute coronary syndrome in chronic kidney disease
CSI · Cardiology · 2020
Ask House about binimetinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team